Skip to main content
NovartisIn development

Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence

Source: Autobound Signal API · 77 signals tracked for Novartis · updated

Get Novartis' live signals in Claude or ChatGPT, or by API

AskWhat changed at Novartis this week? Use Autobound signals for novartis.com.

What happened

Novartis announced positive six-year follow-up results from the Phase III NATALEE trial evaluating Kisqali plus endocrine therapy for stage II and III HR+/HER2- early breast cancer.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Basel, October 23, 2026 – Novartis today announced results from the six-year follow-up analysis of the Phase III NATALEE trial, reporting positive, clinically meaningful overall survival (OS) data with Kisqali ® (ribociclib) plus endocrine therapy (ET) compared to ET alone 1 . The study was in the broadest early breast cancer (eBC) population of patients with stage II and III HR+/HER2- early breast cancer at high risk of recurrence, including those with high-risk node-negative (N0) disease and all node-positive patients 1,2. Kisqali plus ET reduced the risk of death by nearly 20% (19.1%) compared to ET alone (HR=0.809; 95% CI: 0.661-0.989), with consistent overall survival benefit observed across all key subgroups 1. These late-breaking results will be presented at the European Society for Medical Oncology (ESMO) Annual Meeting 2026.

globenewswire.com/news-release/2026/10/23/3387184/0/en/kisqali-shows-...Read the full source

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
Kisqali
Takes effect
Oct 23, 2026
Location
Basel, Basel-Stadt, Switzerland

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical

Extraction

Confidence
95%
Detected
Oct 23, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Novartis and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Novartis this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/dc72f32b-4528-9c4f-d8e0-a785dabccec9 returns this record as JSON. POST /v1/companies/enrich returns every signal for novartis.com.

{
  "signal_id": "dc72f32b-4528-9c4f-d8e0-a785dabccec9",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-23T11:30:00+00:00",
  "company": {
    "name": "Novartis",
    "domain": "novartis.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/10/23/3387184/0/en/kisqali-shows-clinically-meaningful-overall-survival-in-broadest-hr-her2-early-breast-cancer-population-at-high-risk-of-recurrence.html",
    "title": "Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence",
    "excerpt": "Basel, October 23, 2026 – Novartis today announced results from the six-year follow-up analysis of the Phase III NATALEE trial, reporting positive, clinically meaningful overall survival (OS) data with Kisqali ® (ribociclib) plus endocrine therapy (ET) compared to ET alone 1 . The study was in the broadest early breast cancer (eBC) population of patients with stage II and III HR+/HER2- early breast cancer at high risk of recurrence, including those with high-risk node-negative (N0) disease and all node-positive patients 1,2 . Kisqali plus ET reduced the risk of death by nearly 20% (19.1%) compared to ET alone (HR=0.809; 95% CI: 0.661-0.989), with consistent overall survival benefit observed across all key subgroups 1 . These late-breaking results will be presented at the European Society for Medical Oncology (ESMO) Annual Meeting 2026.",
    "product": "Kisqali",
    "summary": "Novartis announced positive six-year follow-up results from the Phase III NATALEE trial evaluating Kisqali plus endocrine therapy for stage II and III HR+/HER2- early breast cancer.",
    "location": "Basel, Switzerland",
    "planning": false,
    "confidence": 0.95,
    "product_data": {
      "name": "Kisqali",
      "full_text": "Kisqali ® (ribociclib)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-23T11:30:00Z",
    "location_data": [
      {
        "city": "Basel",
        "state": "Basel-Stadt",
        "region": "Western Europe",
        "country": "Switzerland",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-10-23",
    "article_sentence": "Novartis today announced results from the six-year follow-up analysis of the Phase III NATALEE trial, reporting positive, clinically meaningful overall survival (OS) data with Kisqali ® (ribociclib) plus endocrine therapy (ET) compared to ET alone 1 ."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.